3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2012-12-28
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of 3-AP when given together
with radiation therapy in treating patients with stage III pancreatic cancer that cannot be
removed by surgery.
3-AP may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Radiation therapy uses high-energy x-rays to kill tumor cells. 3-AP may make tumor
cells more sensitive to radiation therapy. Giving 3-AP together with radiation therapy may
kill more tumor cells.